ReviewWorld journal of oncology2022
Giant Retroperitoneal Liposarcoma: Correlation Between Size and Risk for Recurrence.
Review in World journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Giant Retroperitoneal Liposarcoma Without Organ Invasion: A Rare Case Report.The American journal of case reports · 2026Article
- Article
- Case Report: A giant dedifferentiated liposarcoma in the retroperitoneum.Frontiers in oncology · 2026Article
- Thoughts and challenges of giant retroperitoneal liposarcoma: A case report.World journal of clinical cases · 2025Article
- Review
- Three-Dimensional visualization reconstruction assisted in the treatment of retroperitoneal liposarcoma: a case report.Frontiers in surgery · 2025Article
- Clinicopathological and molecular diagnostic features of liposarcoma: A study of 27 cases.CytoJournal · 2025Article
- Case Report: A 55 kg retroperitoneal liposarcoma.Frontiers in oncology · 2025Article
- Management challenges of a giant retroperitoneal liposarcoma: A case report and review of the literature.International journal of surgery case reports · 2024Article
- Recurrent retroperitoneal liposarcoma with multiple surgeries: a case report.Frontiers in oncology · 2024Article
- Surgical management of giant retroperitoneal liposarcoma: Case report.Rare tumors · 2024Article
- Giant retroperitoneal well differentiated liposarcoma: A case report and literature review.International journal of surgery case reports · 2023Article
- A case of retroperitoneal liposarcoma extending through the inguinal canal to the thigh and lesser trochanter.IJU case reports · 2023Article
- Resection of a giant mediastinal liposarcoma by median sternotomy with vascular reconstruction-a case report.Mediastinum (Hong Kong, China) · 2023Article
- Types of Cancer and Research Covered inWorld journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue sarcomas (STSs) are rare tumors that represent almost 1% of adult malignant tumors. The annual incidence rate for such tumors is 2 - 5/100,000 population. The most common type of STS in adults is liposarcoma, which represents 15-20% of adult STSs. It is of mesodermic origin derived from adipose tissues, and known as the most common primary malignant tumor of the retroperitoneum. Other sites of involvement include the extremities, trunk and to a lesser extent the pleural cavity, esophagus, mediastinum and others. Due to the potential large retroperitoneal space, retroperitoneal liposarcoma (RPL) is usually asymptomatic during the initial phase, developing symptoms at a late stage due to large mass compressing nearby retroperitoneal structures. The average diameter and weight of RPL during diagnosis is 20 - 25 cm and 15 - 20 kg, respectively. Several factors were labelled as risk factors for recurrence, such as histological type, tumor grade, age, resectability and tumor size. Controversy exists regarding the relationship between tumor size and recurrence rate, thus, tumor size as a risk factor for recurrence should be clarified. Although there is no consensus regarding the precise definition of giant RPL, it is defined by several literatures as an RPL of greater than 30 cm in diameter or with weight of more than 20 kg. The main purpose of this article is to review the current English literature regarding giant RPL and examine the relationship between tumor size and risk for recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.